An Efficacy and Safety Trial of Serostim® in the Maintenance of the Treatment Effect Obtained During the Study of Serostim® in Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome

Human Immunodeficiency Virus Infections Clinical Trial

Official title:

Multicenter Open-label, Randomized, Dose-finding, Parallel-group, Safety and Efficacy Trial of Subcutaneous Administration of Serostim® (Mammalian Cell-derived Recombinant Human Growth Hormone, r-hGH) in the Maintenance of the Treatment Effect Obtained During the Study of Serostim® in Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00294918
• Other study ID #: 23056
• Status: Completed
• Phase: Phase 2/Phase 3
• First received: February 17, 2006
• Last updated: March 24, 2014
• Start date: September 2001
• Est. completion date: February 2003

Study information

• Verified date: March 2014
• Source: EMD Serono
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This is an open-label, multi-center, randomized, parallel-group, maintenance trial of Serostim® in subjects who have completed a prior Serostim® Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS) trial (Study 22388). The subjects, who encountered toxicity during the antecedent protocol, will be assigned to a 1 milligram (mg) dose. All other subjects will be randomized in 1:1 ratio, to receive up to 2 mg or 4 mg of Serostim®, beginning from Day 1 of Week 1. Doses will be adjusted downward in subjects weighing less than 55 kilogram (kg). Serostim® therapy will be continued at the assigned doses through Week 12 (Period 1). Subjects, who will encounter toxicity during Period 1, will be assigned to the 1 mg group for Period 2. All other subjects will be randomized in a 1:1 ratio to receive up to 2 mg or 1 mg of Serostim® on a weight adjusted basis. Period 2 therapy will begin on Day 1 of Week 13, continuing through Week 36. Study visits are required at Screening (that is, Final Visit of the antecedent trial), Day 1 of Week 1 (Baseline), and at Weeks 2, 6, 12, 14, 24, 30 and 36.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 142
• Est. completion date: February 2003
• Est. primary completion date: February 2003
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Complete all treatments prescribed by the antecedent protocol (Study 22388)

• Be able and willing to comply with the protocol for the duration of the study, including concomitant therapy restrictions

• Have given written informed consent

• If female, be post-menopausal, surgically sterile, or using adequate contraception

Exclusion Criteria:

• Experienced a protocol defined toxicity or any other adverse event, which caused premature withdrawal from the antecedent study (Study 22388)

• Withdrew from the antecedent study or was discontinued prematurely for any other reason

• Based on the Final Visit evaluations from the antecedent trial, would be required to withdraw from the antecedent protocol, if (theoretically) the antecedent trial continued beyond the Final Visit

• Based on the Final Visit evaluations from the antecedent trial, would be required to temporarily stop or reduce the dose of study drug, if (theoretically) the antecedent trial continued beyond the Final Visit. This does not apply to subjects whose study drug was temporarily stopped or whose study drug dose was reduced prior to the Final Visit (Screening), provided they continued in the antecedent protocol and are stable at the time of the Final Visit (Screening)

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Acquired Immunodeficiency Syndrome
• HIV Infections
• Human Immunodeficiency Virus Infections
• Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS)
• Immunologic Deficiency Syndromes
• Syndrome
• Virus Diseases

Intervention

Drug:
• Serostim®
Serostim® will be administered subcutaneously at a dose of 1 mg to subjects who had encountered toxicity during the antecedent protocol (Study 22388) whereas, other subjects will be randomized in 1:1 ratio, to receive either 2 milligram (mg) or 4 mg (on a weight adjusted basis) daily, starting from Day 1 of Week 1 up to Week 12 (Period 1). During Period 1, subjects who encounter toxicity will receive 1 mg Serostim® subcutaneously, daily for Period 2, starting from Day 1 of Week 13, whereas other subjects will be randomized in a 1:1 ratio to receive either 2 mg or 1 mg (on a weight adjusted basis) up to Week 36.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
EMD Serono

References & Publications (1)

Low-dose Maintenance Therapy with Recombinant Human Growth Hormone Sustains Effects of Previous r-hGH Treatment in HIV+ Patients with Excess Center Fat: Treatment Results at 60 Weeks D P Kotler, C Grunfeld, N Muurahainen, C Wanke, M Thompson, D Bock, J Gertner, and Serostim in the Treatment of Adipose Redistribution Syndrome (STARS) Trial Investigator Group. Abstract. 11th Conference on Retroviruses and Opportunistic Infections. February 8-11, 2004, Moscone West, San Francisco CA, USA.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percent change from Week 12 in trunk fat quantified by Dual-energy X-ray absorptiometry (DXA) at Week 36		Week 12 and Week 36	No
Secondary	Change from Week 12 in ratio of trunk fat to limb fat quantified by DXA at Week 36		Week 12 and Week 36	No
Secondary	Change from Week 12 in weight measured on a calibrated scale at Week 36		Week 12 and Week 36	No
Secondary	Change from Week 12 in total body fat quantified by DXA at Week 36		Week 12 and Week 36	No
Secondary	Change from Week 12 in lean body mass quantified by DXA at Week 36		Week 12 and Week 36	No
Secondary	Change from Week 12 in maximal chest, waist, and hip circumference at Week 36		Week 12 and Week 36	No
Secondary	Change from Week 12 in waist/hip ratio at Week 36		Week 12 and Week 36	No
Secondary	Change from Week 12 in Dorsocervical Fat Pad at Week 36		Week 12 and Week 36	No

External Links

•   Link
•   Full FDA approved prescribing information can be found here